Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund’s top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Masimo Corporation (NASDAQ:MASI). Incorporated in 1989, Masimo Corporation (NASDAQ:MASI) is a medical technology company that provides various patient monitoring technologies, automation, and connectivity solutions. The one-month return of Masimo Corporation (NASDAQ:MASI) was -0.21%, and its shares gained 26.13% of their value over the last 52 weeks. On May 8, 2025, Masimo Corporation (NASDAQ:MASI) stock closed at $153.58 per share with a market capitalization of $8.327 billion. Baron Health Care Fund stated the following regarding Masimo Corporation (NASDAQ:MASI) in its Q1 2025 investor letter: "We initiated a position in Masimo Corporation (NASDAQ:MASI), a medical device company that manufactures and sells a variety of non-invasive patient monitoring technologies. Masimo is the market leader in pulse oximetry, which measures oxygen saturation of arterial blood. The company’s differentiated pulse oximetry technology overcomes the limitations of conventional pulse oximetry by maintaining accuracy in the presence of motion and low perfusion. Masimo SET is the primary pulse oximetry technology used in the top 10 U.S. hospitals. The company has significant intellectual property protection around its technology as well as multi-year customer contracts, creating barriers to entry. The business benefits from a highly recurring revenue model driven by disposable sensors. A team of doctors and nurses in the operating room, utilizing a variety of Masimo's medical technology. Story Continues Masimo Corporation (NASDAQ:MASI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Masimo Corporation (NASDAQ:MASI) at the end of the fourth quarter which was 30 in the previous quarter. Masimo Corporation's (NASDAQ:MASI) first quarter revenue grew 10% to $372 million. While we acknowledge the potential of Masimo Corporation (NASDAQ:MASI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Do You Believe in the Growth Potential of Masimo Corporation (MASI)?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...